Acceptance of Human Papillomavirus Vaccination in Postpartum Women (HPV Acceptance)
This study has been completed.
First Posted: August 8, 2008
Last Update Posted: November 5, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Jason D. Wright, Columbia University
Worldwide cervical cancer remains a major cause mortality among women. It is estimated that each year over 490,000 women are diagnosed with cervical cancer and more than 270,000 die from the disease. While the implementation of widespread screening programs has reduced the burden of cervical cancer, a large percentage of the population still remains unscreened or is underscreened. It is now recognized that human papillomavirus (HPV) is a necessary precursor for the development of cervical cancer. The first vaccine to prevent HPV was recently approved by the Food and Drug Administration and is now available at doctors offices. Despite the availability of a safe and effective means for the prevention of cervical cancer, widespread implementation of vaccination has been extremely difficult. Several potential issues have limited the development of widespread HPV vaccination programs, including cultural and religious beliefs, and limitations in the practicality of administering the vaccine. The overall goals of our work are to improve access to preventive strategies for cervical cancer. In this proposal we will examine the strategy of HPV vaccination for women who have just given birth. We believe that HPV vaccination of these women will be associated with a high level of patient satisfaction and acceptance. If successful, this strategy could play a major role in advancing the acceptance and implementation of HPV vaccination in the United States.
Human Papilloma Virus
||Observational Model: Case-Only
Time Perspective: Prospective
||Acceptance of Human Papillomavirus Vaccination in Postpartum Women
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2012 (Final data collection date for primary outcome measure)
1. To estimate compliance with the HPV vaccine series when initiated in postpartum women.
- To determine patient acceptance and satisfaction with HPV vaccination administered in the postpartum period.
- To determine predictors of compliance with the HPV vaccination series.